Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy

Estrada, Vicente; Domingo, Peré; Suárez-Lozano, Ignacio; Gutiérrez, Félix; Knobel, Hernando; Palacios, Rosario; Antela, Antonio; Blanco, José Ramón; Refoyo, E.

doi:10.1016/j.rceng.2019.05.012

Cited by 2 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since HIV-infection is now a chronic disease, several comorbidities like atherosclerosis and cardiovascular disease all related to aging have become common within the population of people with HIV (Gebo et al, 2010;Clifford and Ances, 2013;Fields et al, 2013;Buggey et al, 2019;Ciccarelli et al, 2019). It is known that HIV-infected individuals have 1.5-2 times higher risk of cardiovascular disease (CVD) due to several factors like chronic inflammation, dyslipidemia, lipid abnormalities like low high-density lipoproteins (HDL), increased triglycerides, and prolonged use of ART (Wang et al, 2015;Zungsontiporn et al, 2016;Prevedel et al, 2017;Ciccarelli et al, 2019;Estrada et al, 2019;Heravi et al, 2019;Palma Reis, 2019). HIV-associated CVD is characterized by extensive loss of cardiomyocytes, increase in fibrous tissues and significant infiltration of immune cells to the heart (Prevedel et al, 2017).…”

Section: Mechanism Of Tat-mediated Cardiovascular Diseasementioning

confidence: 99%

“…In addition, the success of cART and maybe the presence of viral reservoirs has exposed several HIV-associated chronic pathological conditions that were not very apparent before the development of the therapy. Currently, people with HIV live longer with nearly undetectable viral loads (Barouch and Deeks, 2014), however, conditions such neurocognitive and cardiovascular impairments persists in a considerable proportion of the population (Fiala et al, 2004;Coll et al, 2006;Becker et al, 2009;Clifford and Ances, 2013;Anand et al, 2018;Alcaide et al, 2019;Estrada et al, 2019;Eyawo et al, 2019). It is estimated that about 50-60% of people with HIV develop HAND and the incidence of cardiovascular disease is probably higher in the same population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HIV-1 Tat: Role in Bystander Toxicity

Ajasin

Eugenín

2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

HIV Tat protein is a critical protein that plays multiple roles in HIV pathogenesis. While its role as the transactivator of HIV transcription is well-established, other non-viral replication-associated functions have been described in several HIV-comorbidities even in the current antiretroviral therapy (ART) era. HIV Tat protein is produced and released into the extracellular space from cells with active HIV replication or from latently HIV-infected cells into neighboring uninfected cells even in the absence of active HIV replication and viral production due to effective ART. Neighboring uninfected and HIV-infected cells can take up the released Tat resulting in the upregulation of inflammatory genes and activation of pathways that leads to cytotoxicity observed in several comorbidities such as HIV associated neurocognitive disorder (HAND), HIV associated cardiovascular impairment, and accelerated aging. Thus, understanding how Tat modulates host and viral response is important in designing novel therapeutic approaches to target the chronic inflammatory effects of soluble viral proteins in HIV infection.

show abstract

Section: Mechanism Of Tat-mediated Cardiovascular Diseasementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

HIV-1 Tat: Role in Bystander Toxicity

Ajasin

Eugenín

2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…It has been observed that 28.8% of HIV-positive patients are at moderate risk of suffering a cerebrovascular event; the relative risk of myocardial infarction is higher in HIV-positive patients that have taken protease inhibitors (49%) or abacavir (43%). 6 The relative risk of myocardial infarction is increased by 1.26 times in HIV-positive (HIV+) persons who have taken protease inhibitor drugs. 7 The aim of this study was to evaluate the frequency and development of dyslipidemias in a cohort of Mexican adult patients with HIV/AIDS on HAART.…”

mentioning

confidence: 99%

Development of dyslipidemias in a cohort of Mexican adult patients with HIV/AIDS under highly active antiretroviral therapy

López-Rodríguez,

Galván,

Arias-Castelán

2024

Mex J Med Res

View full text Add to dashboard Cite

Dyslipidemias are comorbidities in seropositive patients under highly active antiretroviral therapy (HAART), which increase their risk of complications and reduce their life expectancy. Objective: evaluate the frequency and development of dyslipidemias in seropositive patients with highly active antiretroviral therapy (HAART). Material and method: retrospective cohort study, in recently diagnosed HIV+ patients: 366 men and 59 women. Serum concentrations of total cholesterol (TC), triglycerides (TGC), HDL cholesterol (HDL-c) and LDL cholesterol (LDL-c) were evaluated before starting and at month 6, 24, 36 and 48 with HAART. Results: in both sexes at the beginning of the HAART, 67.1% of low HDL-C levels were obtained. Dyslipidaemia due to TGC and TC increased significantly in all participants after 48 months of HAART (36.9% vs. 52.7% and 7.1% vs. 22.4%, respectively, p<0.05). however, the HDL-C decreased in patients with nucleoside and non-nucleoside reverse transcriptase inhibitor drugs. Discussion: HIV+ patients with HAART have a higher risk of developing dyslipidaemia, an increase in concentrations occurred after 6 months of treatment, a trend that continued positive until 48 months with HAART. Conclusions: dyslipidemias due to TG and TC, as well as low HDL-C are the most frequent in HIV+ patients, which change depending on the time and the type of drug indicated in the HAART.

show abstract

Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy

Cited by 2 publications

References 25 publications

HIV-1 Tat: Role in Bystander Toxicity

HIV-1 Tat: Role in Bystander Toxicity

Development of dyslipidemias in a cohort of Mexican adult patients with HIV/AIDS under highly active antiretroviral therapy

Contact Info

Product

Resources

About